Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

Sibylle Loibl,Andreas Schneeweiss,Jens Huober,Michael Braun,Julia Rey,Jens-Uwe Blohmer,Jenny Furlanetto,Dirk Michael Zahm,Claus Hanusch,Jörg Thomalla,Christian Jackisch,Peter Staib,Theresa Link,Kerstin Rhiem,Christine Solbach,Peter A. Fasching,Nicole Burchardi,Carsten Denkert,Michael Untch

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

2021

Sibylle Loibl
Andreas Schneeweiss
Jens Huober
Michael Braun
Julia Rey
Jens-Uwe Blohmer
Jenny Furlanetto
Dirk Michael Zahm
Claus Hanusch
Jörg Thomalla
Christian Jackisch
Peter Staib
Theresa Link
Kerstin Rhiem
Christine Solbach
Peter A. Fasching
Nicole Burchardi
Carsten Denkert
Michael Untch

506Background: The GeparNuevo trial investigated the addition of durvalumab, an anti-PD-L1 checkpoint inhibitor (CPI), to standard neoadjuvant chemotherapy (NACT) in patients with early TNBC. Durva...

Keywords:

Medicine
Taxane
Internal medicine
Chemotherapy
in patient
Oncology
Anthracycline
Durvalumab
Triple-negative breast cancer
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations